Prevention and medical management of Clostridium difficile infection

BMJ (Online)

Volumn 340, Issue 7747, 2010, Pages 641-646

  Shannon Lowe, J ^a   Matheson, N J ^a   Cooke, F J ^a   Aliyu, S H ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; HUMAN; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 77949740560     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1296     Document Type: Review

References (35)

1. Department of Health and Health Protection Agency. Clostridium difficile infection: How to deal with the problem. 2008. www.hpa.org. uk/webw/ HPAweb&HPAwebStandard/HPAweb-C/1204186173530.
2. Noblett SE, Welfare M, Seymour K. The role of surgery in Clostridium difficile colitis. BMJ 2009;338:b1563.
3. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
4. Centre for Disease Control and Prevention. Severe Clostridium difficile associated disease in populations previously at low risk. MMWR 2005;54:1201-5.
5. NHS Purchasing and Supply Agency. Evaluation report: Clostridium difficile toxin detection assays. 2009. www.pasa.nhs.uk/pasa/Doc.aspx? Path=%5bMN%5d%5bSP%5d/NHSprocurement/CEP/CEP08054.pdf.
6. Commission for Healthcare Audit and Inspection. Investigation into outbreaks of Clostridium difficile at Maidstone and Tunbridge Wells NHS Trust, October 2007.
7. Fawley WN, Freeman J, Smith C, Harmanus C, van den Berg RJ, Kuijper EJ, et al. Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J Clin Microbiol 2008;46:954-60.
8. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
9. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;179:767-72.
10. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-95.
11. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003;54:104-8.
12. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005;(4):CD003543.
13. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
14. Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Engl J Med 2006;354:1201.
15. Cooke FJ, Holmes AH. The missing care bundle: antibiotic prescribing in hospitals. Int J Antimicrob Agents 2007;30:25-9.
16. Wilcox MH, Cunnliffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23-30.
17. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S43-9.
18. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol 2009;30:939-44.
19. Jernigan JA, Siegman-Igra Y, Guerrant RC, Farr BM. A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 1998;19:494-9.
20. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technol Assess 2003;7:1-194.
21. Commission for Healthcare Audit and Inspection. Investigation into outbreaks of Clostridium difficile at Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust, July 2006.
22. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-64.
23. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
24. Wilcox MH, Sandoe JA. Probiotics and diarrhea: data are not widely applicable [letter]. BMJ 2007;335:171.
25. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.
26. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
27. Louie T, Gerson M, Grimard D, Johnson S, Poirier A, Weiss K, Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficileassociated diarrhea (CDAD) [abstract K-4259]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC). ASM Press, 2007.
28. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403-6.
29. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86:15-9.
30. Apisarnthanarak A, Razavi B, Mundy L. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-6.
31. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-8.
32. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S32-42.
33. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40.
34. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
35. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882-4.